Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Novo Nordisk (NYSE:NVO) and maintains a $160 price target.
July 01, 2024 | 3:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Novo Nordisk and maintains a $160 price target.
The reiteration of an Overweight rating and a maintained price target of $160 by a reputable analyst is likely to positively impact investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100